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Big data are abundant in nephrology. We celebrate big data; we
embrace them because of their sample sizes and give them space
in the most respected journals.Wemake policy and funding deci-
sions based on big data. But what happened to the interventional
studies? Could the ready presence of big data be a bane of neph-
rology? What if the interpretations of the big data are flawed?
Few of us really understand the statistical methods that underlie
these big data, so all we read is the conclusion. We will take the
example of a study published in this issue ofNDT to note that the
interpretation of big data by another set of nephrologists could
lead to a conclusion quite contrary to that of the authors.
To publish a paper using big data, we need three things: big
data, an outcome and a statistical method. The article by Chou
et al. [1] has all three ingredients. What if each of these three
ingredients is messy—as is often the case—can we still rely on
the conclusions? We will point out how we might reach a very
different conclusion using the same data presented. We will
question three factors: flaws in the data, selection of the out-
come and the statistical methods. Thus, could that lead to a dif-
ferent conclusion? We do so not to criticize the study of Chou
et al. [1] as much as to illustrate that we should not blindly trust
big data. We use this as an opportunity to call for interventional
studies that are sorely lacking in nephrology.
BIG DATA
The study of Chou et al. [1] asks the question whether change in
blood pressure (BP) during dialysis for end-stage renal disease and
“intradialytic hypotension” is related to mortality. This study is
certainly big. The authors started with 208 820 incident dialysis
patients but ended with 112 013 in the cohort. The 46% drop-out
rate was in large part due to >46 000 patients not being dialyzed
in the participating hemodialysis (HD) units for 60days. Thus,
despite the large sample size, the generalizability is reduced because
these results would not apply to those who did not survive the first
2months—the time at which themortality risk is the greatest.
Big data typically rely on analyzing electronic databases of rou-
tinely gathered clinical information. The quality of these data
may not be the ideal. For instance, this study analyzed peridialytic
BP. However, other measures of BP in HD patients have been
shown to be a superior correlate of mortality. For example, recent
analyses of the prospective Chronic Renal Insufficiency Cohort
found that while peridialytic BP has a U-shaped relationship with
all-cause mortality and cardiovascular events, BP measured out-
side of the HD unit has a linear relationship with both all-cause
mortality [2] and cardiovascular events [3], similar to the experi-
ence in other hypertensive populations. Other reports have
shown home BP measures to be superior to peridialytic BP for
correlation to end-organ damage [4], as well as for predicting car-
diovascular events and all-cause mortality [5].
Additionally, big data cannot analyze that which is not easily
gleaned from electronic databases. In this case there is no informa-
tion available on antihypertensive drug usage or prescribed changes
in dry weight thatmay illuminate whether the observed low BP val-
ues were the result of medical interventions or the consequence of
worsening underlying illness. This distinction is important because
the answer impacts whether and how aggressive dialysis practi-
tioners should be in treating hypertensive HD patients. Although
low BP associates with mortality, meta-analyses of the available
randomized clinical trials of antihypertensive medications in HD
have not shown harm and instead showed benefit in the form of
reduced cardiovascular events, with the effect most pronounced
in the cohort of patients with known hypertension at baseline [6].
OUTCOME DEFINITION
Was the outcome of all-cause mortality chosen by the authors
appropriate? Dialysis patients do not rate all-cause mortality as
a high priority, rather fatigue, energy, ability to travel and qual-
ity of life are more important for them. For HD nurses and tech-
nicians, sudden syncopal episodes and machine alarms may be
more important. Furthermore, if a potential causal link between
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hypotension and poor outcomes is sought, then the most spe-
cific hard outcome to measure would be cardiovascular events
or cardiovascular mortality, not all-cause mortality. While all-
cause mortality can be reliably ascertained in a retrospective
fashion on a large scale, reliable identification of cardiovascular
events requires a prospective study by investigators experienced
with adjudicating such events.
METHODOLOGY
Was the methodology appropriate? The definition of intradia-
lytic hypotension was not standard in this study. The European
Best Practices Guidelines for HD define intradialytic hypoten-
sion as a drop in BP that is both associated with symptoms and
that requires an acute nursing intervention [7]. This definition
focuses on the individual HD session whereas the definitions
for intradialytic hypotension in the report by Chou et al. [1]
used BP values averaged over >3 months and does not use the
standard definition.
Chou et al. [1] report that frequent declines in systolic BP
(SBP) associate with mortality. However, this may not be cause
and effect. Hypotension may simply be a marker of severity of
underlying illness that itself is the cause of subsequent mortality.
This relationship is likely to be most pronounced in a cohort of
more acutely ill patients. Indeed, lower BP has been shown to be
associated with increased mortality for incident peritoneal dial-
ysis (PD) patients, whereas in the same cohort lower BP was
protective for those patients with a dialysis vintage of at least 6
years [8]. Most importantly, when only the incident PD patients
healthy enough to be listed for transplant were analyzed, lower
BP was still protective. In fact, the Chou et al. [1] study includes
findings that support the notion that comorbidity and severity
of illness are likely major contributors to the hypotension asso-
ciated with mortality. For example, the average nadir
SBP< 90mmHg over the incident 3months of HD was associ-
ated with a clinically major hazard ratio>4 without any adjust-
ment, but after full adjustment, including for comorbidities and
markers of inflammation, the hazard ratio for all-cause mortal-
ity at 1 year was down to 1.5. It is certainly possible that if more
granular data were available to allow adjustment for severity
and not just the presence of comorbidities, such as heart failure
class in the 36% of the cohort reported to have a history of con-
gestive heart failure, then the hazard ratios may have been even
further mitigated. It should be noted that whereas a hazard ratio
of 4 may be relevant for individual-level decision making, a haz-
ard ratio of 1.5 is of epidemiological interest only [1].
Most important is the question of statistical adjustment. In a
randomized trial, both known and unknown confounders can
be balanced by randomization, but retrospective studies require
statistical adjustment to account for known confounders. The
study by Chou et al. [1] adjusted for both the predialysis SBP
and predialysis diastolic BP (DBP) simultaneously. In such a
model predicting all-cause mortality, a higher SBP and lower
DBP relates to mortality [9]. This is because the two considered
together assess arterial stiffness. What does it mean when one
adjusts a decline in SBP during dialysis for arterial stiffness?
Could there be an interaction between arterial stiffness and a
decrease in SBP with respect to all-cause mortality? In other
words, is it possible that those with the greatest declines in SBP
have an increased mortality only when they have stiff arteries?
Or could the arterial stiffness be in the causal pathway that
relates a decline in SBP during dialysis to all-cause mortality?
This last question is not simply of academic interest. This is
because statistical adjustment for a factor that lies on the causal
pathway between an exposure and an outcome can fundamen-
tally alter that relationship between the risk factor and the
outcome.
Expounding further on this point of adjustment, the data
were adjusted for ultrafiltration volume and dialysis time, so
effectively, ultrafiltration rate. Is it possible that those who have
the greatest SBP decline with the least ultrafiltration rate have
worse outcomes? These data are not presented, so we cannot
address these questions, but it is clear that the adjustments fun-
damentally change the outcomes. Note in Figure 3B from the
report by Chou et al. [1] in an unadjusted analysis, those with
the smallest decrease in SBP have an increased mortality. Their
Figure 3B, redrawn conceptually as Figure 1, shows that the
lowest sextile had the highest unadjusted mortality. In other
words, if SBP does not decline with dialysis, all-cause mortality
is elevated. The greatest declines in SBP (>50mmHg systolic)
had the lowest hazards for mortality. One may therefore reason-
ably conclude that a decrease in SBP is physiologic and associ-
ated with longer life in a dialysis patient (Figure 1, solid line).
However, when one adjusts for the ultrafiltration volume, SBP,
DBP and dialysis duration, the data are interpreted quite differ-
ently (Figure 1, broken line).
Finally, there is a pearl potentially hidden in the article—not
hypotension, but intradialytic hypertension. Figure 3A from the
paper by Chou et al. [1] shows a strong association between
intradialytic hypertension and 5-year mortality, even after full
adjustment. In fact, only 6% of the cohort had the largest
decrease in SBP (> 50mmHg), while even more patients had
the smallest decrease in SBP (< 15mmHg), at 9% of the cohort.
It is reasonable to focus on this latter group for two reasons.

















Change in Systolic BP
FIGURE 1: In an unadjusted analysis, a greater change in SBP on
dialysis is associated with a decreasing hazard ratio for all-cause mor-
tality, as illustrated by the solid line. After extensive statistical adjust-
ment, the relationship is altered such that a large change in SBP is
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|plausible connection between intradialytic hypertension and
mortality that can be ameliorated by a simple intervention. This
group whose BP hardly decreased may have experienced
increased mortality because of volume overload, as intradialytic
hypertension has previously been associated with volume excess
[10]. Alternatively, the volume overload was recognized by the
treating physicians, who prescribed additional ultrafiltration on
HD such that they now had SBP decrements during HD and
improved mortality. Because the latter analysis was not
performed, even big data cannot answer the question.
CONCLUSIONS
When considering how this study may affect clinical practice
one must consider several caveats related to the limitations of
the design for this retrospective study. Our interpretation is
quite different from that of the authors. We conclude that a
small decrease in SBP (<15mmHg from baseline to nadir,
averaged over 90 days) should trigger an assessment of vol-
ume excess. In those who are volume overloaded, measures to
mitigate this volume excess may lead to a greater decline in
systolic BP during dialysis, which may associate with better
outcomes.
In our opinion, intradialytic hypotension that is clinically
relevant (symptomatic, requiring intervention, as defined by the
European Best Practice Guidelines) has never been adequately
examined, because all big data are samples of convenience.
They only collect what the large dialysis organizations have or
mandate. If we keep relying on these big data, we will continue
to make big mistakes.
Because of the fundamental limitations of retrospective study
design, no firm recommendations can be made regarding man-
agement of BP on HD beyond the truism that it seems prudent to
avoid extremes in BP on HD if possible. As we show above, com-
pletely different conclusions can be made from the same data. To
be sure, big data by themselves are not good or bad. It is what
we do with them, how we interpret them and how we make deci-
sions based on them that makes a difference. Ultimately, prospec-
tive studies and randomized controlled trials are necessary to
determine whether, when, how and to what extent hypertension
or asymptomatic hypotension on HD should be treated. It is time
to plan interventional studies. It is time to rethink.
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